retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Explained for Beginners: Moving
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13












:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)




:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)










